Estelle Charvet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Estelle Charvet has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Maxime Battistella
INSERM U1342 Saint-Louis Research Institute , Paris
3 shared publications - Adèle de Masson
Service de Dermatologie Hôpital Saint Louis, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
2 shared publications C. Cassius
Service de Dermatologie, Hôpital Saint-Louis, AP-HP, Paris, France
2 shared publications- Marie Jachiet
Dermatology Department Saint Louis Hospital Paris France
2 shared publications - Thibault Mahévas
Dermatology Department Hôpital Saint Louis, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
2 shared publications A. Mekinian
Sorbonne University, Department of Internal Medicine, AP-HP, Saint Antoine Hospital, 75012 Paris, France
1 shared publication
Latest Publications
- 2 June 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (3) , 103492
Successful use of thalidomide in treating metastatic Crohn’s disease
- 2 June 2026
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 153 (3) , 103492
Successful use of thalidomide in treating metastatic Crohn’s disease
- Open Access
- 6 July 2024
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 151 (3) , 103286
Recurrent cervical swelling syndrome as a rare cause of left supraclavicular edema: Case series and literature review
- 6 July 2024
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 151 (3) , 103286
Open AccessRecurrent cervical swelling syndrome as a rare cause of left supraclavicular edema: Case series and literature review
- Open Access
- 14 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3293-3298
Cutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms
- 14 June 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (12) , 3293-3298
Open AccessCutaneous clonal mature plasmacytoid dendritic cell dermatosis in patients with myeloid neoplasms
- 30 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2525-2529.e5
Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing
- 30 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2525-2529.e5
Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing
- 1 December 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A235
Histoplasmoses cutanées de présentation clinique et histologique pseudo tumorale : 2 cas
- 1 December 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A235
Histoplasmoses cutanées de présentation clinique et histologique pseudo tumorale : 2 cas
- 16 April 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (7) , 1334-1335
Efficacy of dupilumab for controlling severe atopic dermatitis with dominant‐negative CARD11 variant
Hypomorphic dominant‐negative mutations in Caspase Recruitment Domain‐containing Protein 11 (CARD11) is a rare cause of severe atopic dermatitis. CARD11 is a membrane protein involved in TCR signalling via the NF‐kB pathway that has been identified as a predisposition locus for severe atopy. A loss of function activity of CARD11 due to a dominant‐negative effect of CARD11 variant leads to severe atopic dermatitis associated with a defective T cell response that polarize toward a Th2 phenotype. We report the successful treatment of severe atopic dermatitis with dominant‐negative CARD11 variant with Dupilumab.
- 16 April 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (7) , 1334-1335
Efficacy of dupilumab for controlling severe atopic dermatitis with dominant‐negative CARD11 variant
Hypomorphic dominant‐negative mutations in Caspase Recruitment Domain‐containing Protein 11 (CARD11) is a rare cause of severe atopic dermatitis. CARD11 is a membrane protein involved in TCR signalling via the NF‐kB pathway that has been identified as a predisposition locus for severe atopy. A loss of function activity of CARD11 due to a dominant‐negative effect of CARD11 variant leads to severe atopic dermatitis associated with a defective T cell response that polarize toward a Th2 phenotype. We report the successful treatment of severe atopic dermatitis with dominant‐negative CARD11 variant with Dupilumab.